Antibodies targeting CD38, a NAD⁺-degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD⁺ to enhance the efficacy of anti-CD38-based immunotherapies in MM.

中文翻译：

---

靶向NAD +合成以增强多发性骨髓瘤基于CD38的免疫治疗。

靶向CD38（一种NAD ⁺降解酶）的抗体已成为对抗多发性骨髓瘤（MM）的一种有前途的免疫疗法。目前，关于抗CD38抗体确立其治疗作用的机制了解甚少。在这里，我们提倡消除NAD ⁺以增强MM中基于抗CD38的免疫疗法的功效。